Dry powder inhaler is a medical device that delivers formulation
using the pulmonary route for systemic or local effect. The combined
use of powdered formulations and device performance provides a safe,
reliable, bioequivalent, and efficient method of drug delivery into
the lungs. The device performance depends upon the air inlet size,
impaction angle of the powder, mouthpiece length, grid structure, and
mouth piece configuration. Some of the Food and Drug Administration
(FDA) approved dry powder inhalers include mono-drug products such as
Zanamivir, Umeclidinium, Tobramycin, Tiotropium, Salmeterol,
Mometasone, Loxapine, Insulin, Indacaterol, Glycopyrronium,
Formoterol, Fluticasone, Budesonide, Albuterol, Aclidinium, and
others. While dual drug products include Umeclidinium + Vilanterol,
Glycopyrronium + Indacaterol, Fluticasone + Vilanterol, Fluticasone +
Salmeterol, and others. The European Medicines Agency (EMA) approved
dry powder inhaler dual drug as well as mono-drug products include
Umeclidinium + Vilanterol , Glycopyrronium + Indacaterol, Fluticasone
+ Vilanterol, Fluticasone + Salmeterol, Budesonide + Formoterol,
Aclidinium + Formoterol, Umeclidinium, Indacaterol, Glycopyrronium,
and Aclidinium.
Drivers of the global dry powder inhalers market are development of
novel device architectures, advances in particle engineering, and
research advancements in powder formulations. More efficient designs
of inhalers, and improved particle properties are expanding the range
of active compounds and growing new opportunities for dry powder
inhaler device that can be effectively delivered to the lung.
Furthermore, increasing geriatric population encourages managed care
initiatives such as self-administration of drug therapies and home
health care. This is likely to boost the growth of the global dry
powder inhalers market. Increasing inclination toward cost-effective
and patient friendly therapies increase the demand for dry powder
inhalers. Inhaled drug administration and dry powder inhalers are
expected to evolve during the forecast period owing to
commercialization of therapeutic drugs and advancements in
pharmaceutical development.
The global dry powder inhalers market can be segmented based on
product type, performance level, therapy type, usage type, and
region. In terms of product type, the market can be classified into
canister/cartridge based, blister based, capsule based, and others.
Based on performance level, the market can be divided into
interpatient variability, dose metering accuracy, mechanism of
aerosolization, and de-agglomeration. In terms of usage type, the
global dry powder inhalers market can be categorized into single-use
disposable devices and multi-use devices.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30638
The multi-use devices segment accounted for a larger market share in
2016 owing to growing awareness. However, advancements in research &
development and addition of rescue medications, analgesics, and
vaccines agents are anticipated to drive the single-use disposable
devices segment during the forecast period. In terms of therapy type,
the global dry powder inhalers market can be classified into
neurological disorder, metabolic conditions, infectious diseases,
hereditary diseases, systemic indications, bronchospasm, chronic
obstructive pulmonary disease (COPD), asthma, upper respiratory
diseases, and others. In 2016, chronic obstructive pulmonary disease
(COPD) accounted for a large market share owing to high prevalence.
Geographically, the global dry powder inhalers market can be divided
into Asia Pacific, North America, Latin America, Europe, and Middle
East & Africa. North America accounted for a large market share
in 2016 owing to high geriatric population and increasing research &
development activities. Europe held the second largest market share
due to growing government facilities and initiatives to combat and
control various diseases and disorders. Asia Pacific is anticipated
to grow during the forecast period owing to rising prevalence of
infections and other diseases, especially in the emerging economies
such as China and India.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=30638<ype=S
Key players in the global dry powder inhalers market are Orion,
Novartis, MicroDose Therapeutx, Meda, Mannkind, Mantecorp, Hovione,
GlaxoSmithKline, Civitas/Alkermes, Cipla, Chiesi, Boehringer
Ingelheim, AstraZeneca, and Aerovance, among others.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment